FOLD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Amicus Therapeutics Inc (FOLD) is not a strong buy for a beginner, long-term investor at this moment. While the company has shown revenue growth and has a pending acquisition by BioMarin, the stock's technical indicators are neutral, insider selling is high, and analysts have downgraded their ratings. Additionally, there are no strong proprietary trading signals or significant catalysts to suggest immediate upside potential.
The technical indicators are mixed. The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 48.835, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 14.334, with minor support and resistance levels close by, suggesting limited price movement in the short term.
Additionally, the pending acquisition by BioMarin for $4.8 billion could provide stability and long-term value.
Jefferies downgraded the stock to Hold, citing no additional takeover bids expected. Insider selling has increased by 110.68% in the last month, which may indicate a lack of confidence from company insiders. The MACD and RSI do not indicate strong bullish momentum.
In Q4 2025, revenue increased by 23.72% YoY to $185.21 million, but net income dropped by 88.53% YoY to $1.69 million. EPS also declined by 80% YoY to $0.01, and gross margin dropped to 84.64%. While revenue growth is strong, profitability metrics are deteriorating.
Jefferies downgraded the stock to Hold with a price target of $14.50, down from $16, citing limited takeover interest. Citi initiated coverage with a Buy rating and a $17 price target, highlighting strong sales potential for Galafold and PomOp. However, the overall sentiment is mixed, with a recent downgrade overshadowing positive coverage.
